Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$21.03
-5.4%
$19.83
$8.89
$26.66
$914.17MN/A998,862 shs416,092 shs
LivaNova PLC stock logo
LIVN
LivaNova
$50.69
-2.7%
$53.58
$32.48
$58.91
$2.77B0.95523,729 shs322,261 shs
Envista Holdings Corporation stock logo
NVST
Envista
$19.10
-5.4%
$20.71
$14.22
$23.00
$3.17B1.012.09 million shs3.58 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$63.76
-2.7%
$66.76
$41.50
$90.32
$3.39B-2.752.20 million shs1.04 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%-5.53%-20.37%+63.91%+2,102,999,900.00%
LivaNova PLC stock logo
LIVN
LivaNova
0.00%-5.02%-9.84%+15.28%-3.50%
Envista Holdings Corporation stock logo
NVST
Envista
0.00%-8.37%-9.25%-4.71%+5.35%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+7.68%+18.91%-22.96%+16.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$21.03
-5.4%
$19.83
$8.89
$26.66
$914.17MN/A998,862 shs416,092 shs
LivaNova PLC stock logo
LIVN
LivaNova
$50.69
-2.7%
$53.58
$32.48
$58.91
$2.77B0.95523,729 shs322,261 shs
Envista Holdings Corporation stock logo
NVST
Envista
$19.10
-5.4%
$20.71
$14.22
$23.00
$3.17B1.012.09 million shs3.58 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$63.76
-2.7%
$66.76
$41.50
$90.32
$3.39B-2.752.20 million shs1.04 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%-5.53%-20.37%+63.91%+2,102,999,900.00%
LivaNova PLC stock logo
LIVN
LivaNova
0.00%-5.02%-9.84%+15.28%-3.50%
Envista Holdings Corporation stock logo
NVST
Envista
0.00%-8.37%-9.25%-4.71%+5.35%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+7.68%+18.91%-22.96%+16.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2.69
Moderate Buy$24.4416.24% Upside
LivaNova PLC stock logo
LIVN
LivaNova
2.50
Moderate Buy$59.7117.80% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.24
Hold$21.0810.35% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
2.93
Moderate Buy$115.9281.80% Upside

Current Analyst Ratings Breakdown

Latest BBNX, NVST, SLNO, and LIVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Envista Holdings Corporation stock logo
NVST
Envista
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
10/8/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
LivaNova PLC stock logo
LIVN
LivaNova
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Envista Holdings Corporation stock logo
NVST
Envista
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$125.00
10/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$125.00
10/1/2025
LivaNova PLC stock logo
LIVN
LivaNova
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuyNeutral$55.00
10/1/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetNeutralBuy$18.00 ➝ $26.00
10/1/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$18.00 ➝ $26.00
10/1/2025
LivaNova PLC stock logo
LIVN
LivaNova
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$55.00
(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$65.12M14.04N/AN/A($5.72) per share-3.68
LivaNova PLC stock logo
LIVN
LivaNova
$1.31B2.11$4.24 per share11.95$24.31 per share2.09
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.26$1.67 per share11.47$17.05 per share1.12
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$32.66M103.76N/AN/A$5.68 per share11.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$54.76MN/A0.00N/AN/AN/AN/AN/A
LivaNova PLC stock logo
LIVN
LivaNova
$63.23M-$3.89N/A16.14N/A-16.13%14.57%6.91%11/5/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3259.6915.791.022.11%4.84%2.68%10/30/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)

Latest BBNX, NVST, SLNO, and LIVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2025Q3 2025
LivaNova PLC stock logo
LIVN
LivaNova
$0.91N/AN/AN/A$342.32 millionN/A
11/5/2025Q3 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$0.08N/AN/AN/A$47.46 millionN/A
10/30/2025Q3 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.27N/AN/AN/A$639.49 millionN/A
8/6/2025Q2 2025
LivaNova PLC stock logo
LIVN
LivaNova
$0.84$1.05+$0.21$0.50$332.20 million$352.50 million
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/29/2025Q2 2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/AN/AN/AN/AN/A
LivaNova PLC stock logo
LIVN
LivaNova
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
14.68
13.79
LivaNova PLC stock logo
LIVN
LivaNova
0.31
1.29
1.09
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01

Institutional Ownership

CompanyInstitutional Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
LivaNova PLC stock logo
LIVN
LivaNova
97.64%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
LivaNova PLC stock logo
LIVN
LivaNova
0.29%
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
29443.47 millionN/AN/A
LivaNova PLC stock logo
LIVN
LivaNova
2,90054.60 million54.44 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300166.18 million165.09 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable

Recent News About These Companies

TD Cowen Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
Soleno: Blockbuster Launch In Progress

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beta Bionics stock logo

Beta Bionics NASDAQ:BBNX

$21.03 -1.20 (-5.40%)
As of 10/10/2025 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

LivaNova stock logo

LivaNova NASDAQ:LIVN

$50.69 -1.42 (-2.73%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$50.69 0.00 (0.00%)
As of 10/10/2025 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Envista stock logo

Envista NYSE:NVST

$19.10 -1.09 (-5.40%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$19.35 +0.25 (+1.31%)
As of 06:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$63.76 -1.80 (-2.75%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$64.60 +0.84 (+1.32%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.